The Future of Biotech and AI

In this episode of the CanadianSME Small Business Podcast, our host Maheen, sit down with Liran Belenzon , CEO of BenchSci, to explore how AI is transforming the biotech industry and what it takes to scale a high-impact startup in Canada’s competitive tech ecosystem. With AI-driven drug discovery projected to grow at a CAGR of 40% by 2030, BenchSci has emerged as a global leader, partnering with 16 of the top 20 pharmaceutical companies and securing over $200 million in funding from investors like Google’s Gradient Ventures and Al Gore’s Generation Investment Management. Key Highlights: The Future of AI in Biotech – How AI is accelerating drug discovery and transforming scientific research. Scaling a Biotech Startup – The biggest challenges BenchSci faced and how they overcame them. Securing Top-Tier Investors – Strategies for attracting funding from Google’s Gradient Ventures and other major backers. Building High-Performance Teams – How BenchSci scaled from a small startup to a 300+ person global biotech leader. What’s Next for BenchSci – The biggest biotech and AI breakthroughs to watch for in the next five years. Special Thanks to Our Partners: RBC: https://www.rbcroyalbank.com/dms/business/accounts/beyond-banking/index.html UPS: https://solutions.ups.com/ca-beunstoppable.html?WT.mc_id=BUSMEWA IHG Hotels and Resorts: https://businessedge.ihg.com/s/registration?language=en_US&CanSME Google: https://www.google.ca/ For more expert insights, visit www.canadiansme.ca and subscribe to the CanadianSME Small Business Magazine. Stay innovative, stay informed, and thrive in the digital age! Disclaimer: The information shared in this podcast is for general informational purposes only and should not be considered as direct financial or business advice. Always consult with a qualified professional for advice specific to your situation